¹Ì¼÷¾Æ¿¡¼ Octreotide¸¦ »ç¿ëÇÏ¿© Ä¡·áÇÑ ¼±Ãµ¼º À¯¹ÌÈä 1·Ê
Treatment of Congenital Chylothorax in a Premature Infant using Octreotide
¾ÈÀ±Áø, ÀüÀ¯ÈÆ, ±èâÈÖ, ±è¼º½Å, ¹ÚÀç¿Á,
¼Ò¼Ó »ó¼¼Á¤º¸
¾ÈÀ±Áø ( Ahn Yoon-Jin )
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀüÀ¯ÈÆ ( Jeon You-Hoon )
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
±èâÈÖ ( Kim Chang-Hwi )
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
±è¼º½Å ( Kim Sung-Shin )
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
¹ÚÀç¿Á ( Park Jae-Ock )
¼øõÇâ´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
KMID : 0438520060130020261
Abstract
Chylothorax, defined as escape of chyle from the thoracic duct into the thoracic cavity, is the most common cause of pleural effusion during the neonatal period. The use of octreotide, a synthetic analogue of the somatostatin, for the treatment of congenital idiopathic chylothorax, has not been previously reported in Korea. We report here a case of idiopathic congenital chylothrax successfully treated with octreotide in a premature infant who showed no response to conservative therapies.
Å°¿öµå
Congenital;Chylothorax;Somatostatin;Octreotide;Prematurity
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸